Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Oral Hormone Replacement Therapy Raises Blood Clot RiskKey Points Oral hormone replacement therapy.
GLP-1 Health Information: Quality, Completeness, & EngagementKey Points A study assessed 128.
DNA Damage Response May Drive Biological AgingKey Points Chronic DNA damage response.
Maternal Diet Fails to Reduce Infant Egg and Peanut AllergyKey Points A large Australian randomized.
Psychedelic-Assisted Psychotherapy: Music in TreatmentKey Takeaways Psychedelic-assisted psychotherapy combines psychedelic.
Cardiovascular Frailty Links Heart Health and AgingKey Points Cardiovascular frailty may connect.
Laser Blended Vision: Simple Test Predicts SuccessKey Points A simple phoropter-based test.
Pink Noise Boosts Brain Waste Clearance During SleepKey Points Pink noise delivered during.
Psilocybin Microdosing Research Raises Key QuestionsKey points: Psilocybin microdosing research shows.
Maternal Illness Linked to Epigenetic Fetal Brain ChangesMaternal illness during pregnancy may influence.
Leave a Comment